rayner pharmaceuticals limited
rayner pharmaceuticals limited Company Information
Company Number
08283451
Next Accounts
Sep 2025
Shareholders
rayner surgical group ltd
Group Structure
View All
Industry
Wholesale of pharmaceutical goods
Registered Address
the ridley innovation centre, 10 dominion way, worthing, west sussex, BN14 8AQ
Website
www.rayneropticians.co.ukrayner pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of RAYNER PHARMACEUTICALS LIMITED at £4.7m based on a Turnover of £4.5m and 1.04x industry multiple (adjusted for size and gross margin).
rayner pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of RAYNER PHARMACEUTICALS LIMITED at £34.3m based on an EBITDA of £3.3m and a 10.39x industry multiple (adjusted for size and gross margin).
rayner pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of RAYNER PHARMACEUTICALS LIMITED at £22.9m based on Net Assets of £12m and 1.91x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Rayner Pharmaceuticals Limited Overview
Rayner Pharmaceuticals Limited is a live company located in worthing, BN14 8AQ with a Companies House number of 08283451. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in November 2012, it's largest shareholder is rayner surgical group ltd with a 100% stake. Rayner Pharmaceuticals Limited is a established, small sized company, Pomanda has estimated its turnover at £4.5m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Rayner Pharmaceuticals Limited Health Check
Pomanda's financial health check has awarded Rayner Pharmaceuticals Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 5 areas for improvement. Company Health Check FAQs
6 Strong
0 Regular
5 Weak
Size
annual sales of £4.5m, make it smaller than the average company (£24.7m)
£4.5m - Rayner Pharmaceuticals Limited
£24.7m - Industry AVG
Growth
3 year (CAGR) sales growth of 14%, show it is growing at a faster rate (5.2%)
14% - Rayner Pharmaceuticals Limited
5.2% - Industry AVG
Production
with a gross margin of 79%, this company has a lower cost of product (29.5%)
79% - Rayner Pharmaceuticals Limited
29.5% - Industry AVG
Profitability
an operating margin of 70.3% make it more profitable than the average company (4.1%)
70.3% - Rayner Pharmaceuticals Limited
4.1% - Industry AVG
Employees
with 3 employees, this is below the industry average (36)
3 - Rayner Pharmaceuticals Limited
36 - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- - Rayner Pharmaceuticals Limited
- - Industry AVG
Efficiency
resulting in sales per employee of £1.5m, this is more efficient (£667.8k)
£1.5m - Rayner Pharmaceuticals Limited
£667.8k - Industry AVG
Debtor Days
it gets paid by customers after 89 days, this is later than average (58 days)
89 days - Rayner Pharmaceuticals Limited
58 days - Industry AVG
Creditor Days
its suppliers are paid after 76 days, this is slower than average (29 days)
76 days - Rayner Pharmaceuticals Limited
29 days - Industry AVG
Stock Days
it holds stock equivalent to 130 days, this is more than average (66 days)
130 days - Rayner Pharmaceuticals Limited
66 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 2 weeks, this is less cash available to meet short term requirements (11 weeks)
2 weeks - Rayner Pharmaceuticals Limited
11 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 32.9%, this is a lower level of debt than the average (54.1%)
32.9% - Rayner Pharmaceuticals Limited
54.1% - Industry AVG
RAYNER PHARMACEUTICALS LIMITED financials
Rayner Pharmaceuticals Limited's latest turnover from December 2023 is £4.5 million and the company has net assets of £12 million. According to their latest financial statements, Rayner Pharmaceuticals Limited has 3 employees and maintains cash reserves of £331 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 4,538,000 | 3,757,000 | 3,673,000 | 3,082,000 | 3,353,000 | 3,918,000 | 4,195,000 | 1,161,000 | |||
| Other Income Or Grants | |||||||||||
| Cost Of Sales | 953,000 | 923,000 | 918,000 | 792,000 | 1,099,000 | 1,451,000 | 1,694,000 | 441,000 | |||
| Gross Profit | 3,585,000 | 2,834,000 | 2,755,000 | 2,290,000 | 2,254,000 | 2,467,000 | 2,501,000 | 720,000 | |||
| Admin Expenses | 394,000 | 510,000 | 367,000 | 318,000 | 640,000 | 464,000 | 1,022,000 | 704,000 | |||
| Operating Profit | 3,191,000 | 2,324,000 | 2,388,000 | 1,972,000 | 1,614,000 | 2,003,000 | 1,479,000 | 16,000 | |||
| Interest Payable | |||||||||||
| Interest Receivable | |||||||||||
| Pre-Tax Profit | 3,191,000 | 2,324,000 | 2,388,000 | 1,972,000 | 1,614,000 | 2,003,000 | 1,479,000 | 16,000 | |||
| Tax | -931,000 | -417,000 | -438,000 | -352,000 | -304,000 | -261,000 | -277,000 | -30,000 | |||
| Profit After Tax | 2,260,000 | 1,907,000 | 1,950,000 | 1,620,000 | 1,310,000 | 1,742,000 | 1,202,000 | -14,000 | |||
| Dividends Paid | |||||||||||
| Retained Profit | 2,260,000 | 1,907,000 | 1,950,000 | 1,620,000 | 1,310,000 | 1,742,000 | 1,202,000 | -14,000 | |||
| Employee Costs | 566,000 | 230,000 | |||||||||
| Number Of Employees | 3 | 3 | 7 | 14 | |||||||
| EBITDA* | 3,301,000 | 2,471,000 | 2,506,000 | 2,090,000 | 1,810,000 | 2,137,000 | 1,630,000 | 55,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 8,000 | 31,000 | |||||||||
| Intangible Assets | 494,000 | 604,000 | 751,000 | 869,000 | 987,000 | 1,183,000 | 1,309,000 | 1,417,000 | |||
| Investments & Other | |||||||||||
| Debtors (Due After 1 year) | |||||||||||
| Total Fixed Assets | 494,000 | 604,000 | 751,000 | 869,000 | 987,000 | 1,183,000 | 1,317,000 | 1,448,000 | |||
| Stock & work in progress | 342,000 | 257,000 | 163,000 | 322,000 | 328,000 | 464,000 | 748,000 | 660,000 | |||
| Trade Debtors | 1,112,000 | 731,000 | 737,000 | 721,000 | 808,000 | 755,000 | 755,000 | 973,000 | |||
| Group Debtors | 15,574,000 | 13,679,000 | 10,842,000 | 8,797,000 | 6,113,000 | 2,846,000 | 1,221,000 | ||||
| Misc Debtors | 1,000 | 3,000 | 4,000 | 45,000 | |||||||
| Cash | 331,000 | 52,000 | 471,000 | 126,000 | 513,000 | 700,000 | 606,000 | 889,000 | |||
| misc current assets | |||||||||||
| total current assets | 17,359,000 | 14,719,000 | 12,214,000 | 9,966,000 | 7,762,000 | 4,768,000 | 3,334,000 | 2,567,000 | |||
| total assets | 17,853,000 | 15,323,000 | 12,965,000 | 10,835,000 | 8,749,000 | 5,951,000 | 4,651,000 | 4,015,000 | |||
| Bank overdraft | |||||||||||
| Bank loan | |||||||||||
| Trade Creditors | 199,000 | 203,000 | 86,000 | 174,000 | 56,000 | 323,000 | 139,000 | 373,000 | |||
| Group/Directors Accounts | 5,532,000 | 5,239,000 | 4,941,000 | 4,666,000 | 4,286,000 | 2,400,000 | 2,981,000 | 2,766,000 | |||
| other short term finances | |||||||||||
| hp & lease commitments | |||||||||||
| other current liabilities | 121,000 | 129,000 | 84,000 | 95,000 | 125,000 | 213,000 | 201,000 | 613,000 | |||
| total current liabilities | 5,852,000 | 5,571,000 | 5,111,000 | 4,935,000 | 4,467,000 | 2,936,000 | 3,321,000 | 3,752,000 | |||
| loans | |||||||||||
| hp & lease commitments | |||||||||||
| Accruals and Deferred Income | |||||||||||
| other liabilities | |||||||||||
| provisions | 24,000 | 35,000 | 44,000 | 40,000 | 42,000 | 85,000 | 142,000 | 277,000 | |||
| total long term liabilities | 24,000 | 35,000 | 44,000 | 40,000 | 42,000 | 85,000 | 142,000 | 277,000 | |||
| total liabilities | 5,876,000 | 5,606,000 | 5,155,000 | 4,975,000 | 4,509,000 | 3,021,000 | 3,463,000 | 4,029,000 | |||
| net assets | 11,977,000 | 9,717,000 | 7,810,000 | 5,860,000 | 4,240,000 | 2,930,000 | 1,188,000 | -14,000 | |||
| total shareholders funds | 11,977,000 | 9,717,000 | 7,810,000 | 5,860,000 | 4,240,000 | 2,930,000 | 1,188,000 | -14,000 |
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Operating Profit | 3,191,000 | 2,324,000 | 2,388,000 | 1,972,000 | 1,614,000 | 2,003,000 | 1,479,000 | 16,000 | |||
| Depreciation | 8,000 | 16,000 | 9,000 | ||||||||
| Amortisation | 110,000 | 147,000 | 118,000 | 118,000 | 196,000 | 126,000 | 135,000 | 30,000 | |||
| Tax | -931,000 | -417,000 | -438,000 | -352,000 | -304,000 | -261,000 | -277,000 | -30,000 | |||
| Stock | 85,000 | 94,000 | -159,000 | -6,000 | -136,000 | -284,000 | 88,000 | 660,000 | |||
| Debtors | 2,276,000 | 2,830,000 | 2,062,000 | 2,597,000 | 3,317,000 | 1,624,000 | 962,000 | 1,018,000 | |||
| Creditors | -4,000 | 117,000 | -88,000 | 118,000 | -267,000 | 184,000 | -234,000 | 373,000 | |||
| Accruals and Deferred Income | -8,000 | 45,000 | -11,000 | -30,000 | -88,000 | 12,000 | -412,000 | 613,000 | |||
| Deferred Taxes & Provisions | -11,000 | -9,000 | 4,000 | -2,000 | -43,000 | -57,000 | -135,000 | 277,000 | |||
| Cash flow from operations | -14,000 | -717,000 | 70,000 | -767,000 | -2,073,000 | 675,000 | -478,000 | -390,000 | |||
| Investing Activities | |||||||||||
| capital expenditure | |||||||||||
| Change in Investments | |||||||||||
| cash flow from investments | |||||||||||
| Financing Activities | |||||||||||
| Bank loans | |||||||||||
| Group/Directors Accounts | 293,000 | 298,000 | 275,000 | 380,000 | 1,886,000 | -581,000 | 215,000 | 2,766,000 | |||
| Other Short Term Loans | |||||||||||
| Long term loans | |||||||||||
| Hire Purchase and Lease Commitments | |||||||||||
| other long term liabilities | |||||||||||
| share issue | |||||||||||
| interest | |||||||||||
| cash flow from financing | 293,000 | 298,000 | 275,000 | 380,000 | 1,886,000 | -581,000 | 215,000 | 2,766,000 | |||
| cash and cash equivalents | |||||||||||
| cash | 279,000 | -419,000 | 345,000 | -387,000 | -187,000 | 94,000 | -283,000 | 889,000 | |||
| overdraft | |||||||||||
| change in cash | 279,000 | -419,000 | 345,000 | -387,000 | -187,000 | 94,000 | -283,000 | 889,000 |
rayner pharmaceuticals limited Credit Report and Business Information
Rayner Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for rayner pharmaceuticals limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other small companies, companies in BN14 area or any other competitors across 12 key performance metrics.
rayner pharmaceuticals limited Ownership
RAYNER PHARMACEUTICALS LIMITED group structure
Rayner Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
2 parents
RAYNER PHARMACEUTICALS LIMITED
08283451
rayner pharmaceuticals limited directors
Rayner Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Mr Alan Hemmant (Mar 2023) and Mr Timothy Clover (Mar 2023).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Alan Hemmant | United Kingdom | 43 years | Mar 2023 | - | Director |
| Mr Timothy Clover | United Kingdom | 58 years | Mar 2023 | - | Director |
| Mr David Allan | England | 60 years | May 2023 | - | Director |
P&L
December 2023turnover
4.5m
+21%
operating profit
3.2m
+37%
gross margin
79%
+4.73%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2023net assets
12m
+0.23%
total assets
17.9m
+0.17%
cash
331k
+5.37%
net assets
Total assets minus all liabilities
rayner pharmaceuticals limited company details
company number
08283451
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
November 2012
age
13
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
December 2023
previous names
rayner & keeler limited (September 2016)
rayner & keeler limited limited (August 2014)
See moreaccountant
-
auditor
DELOITTE LLP
address
the ridley innovation centre, 10 dominion way, worthing, west sussex, BN14 8AQ
Bank
NATIONAL WESTMINSTER BANK PLC
Legal Advisor
-
rayner pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 3 charges/mortgages relating to rayner pharmaceuticals limited. Currently there are 2 open charges and 1 have been satisfied in the past.
rayner pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for RAYNER PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
rayner pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
